Han Kun Law Offices represented Shanghai Wankexin Biotechnology Partnership (Limited Partnership) ("Wankexin") in completing the acquisition of control of Kanghua Biological (300841.SZ) through agreement transfer and voting rights entrustment, pursuant to which Wankexin acquired an aggregate of 29.99% voting rights in Kanghua Biological, with a transaction consideration of RMB 1.851 billion. Wankexin was established by Shanghai Shangshi Biomedical Management Consulting Co., Ltd. as the general partner, together with Shanghai Biomedical M&A Private Equity Fund Partnership Enterprise (Limited Partnership) and Shanghai Pharmaceuticals (GROUP) Corp. as limited partners.
Kanghua Biological is primarily engaged in the research, development, manufacturing, and sale of human vaccines, with approved products including freeze-dried human rabies vaccine (human diploid cell) and ACYW135 meningococcal polysaccharide vaccine. This transaction aligns with the Opinions of the CSRC on Deepening the Market Reform for M&A and Restructuring of Listed Companies ("Sixth M&A Guidelines"), leveraging the acquirer's high-quality resources to further enhance Kanghua Biological's operational governance and empower the listed company.
In this transaction, Han Kun represented Wankexin throughout the entire process, including transaction structure design, drafting, revision, and negotiation of transaction documents, information disclosure for the listed company, antitrust filing, and project closing, providing comprehensive, professional, and efficient legal services, demonstrating Han Kun's outstanding legal capabilities in advising on acquiring control of listed companies.
